Purpose of Review <p>In healthcare, biomarkers are essential for personalised medicine, prognosis, therapy response, and disease diagnosis. They make it possible for better patient outcomes, early detection, and intervention. They support customised treatment programs, anticipate the progress of diseases, and direct treatment decisions. Different types of cancer biomarkers fordiagnosis, detection processes, challenges, and future perspectives are discussed in this review study. Preclinical studies of cancer biomarkers are also includedin the article with particular attention paid to developments in testing procedures, knowledge of the immune microenvironment, biological characterisation, and tumour profiling.</p> Recent Findings <p>A gene, gene product, etc. that is produced during cell division and genetic alteration can be a cancer biomarker. Numerous studies have identified unique biomarkers that allow for the early identification of a variety of cancer types, including colorectal, lung, breast, kidney, pancreatic, and oral malignancies. Examining human biological fluids such as blood, urine, plasma, serum, and tumor cells confirms their existence.Given the needs of point of care, cancer biomarkers have the potential to be utilized in both treatment monitoring and cancer prediction. Recent research has demonstrated that molecular biomarkers provide important information for the early identification of malignancies that could otherwise be difficult to identify. By presenting a comprehensive, interdisciplinary perspective on cancer biomarkers and integrating diagnostic and therapeutic concepts across a number of cancer types, this article stands out from earlier research. This review fills a significant gap by addressing a range of cancer types and addressing biomarkers in numerous biological matrices. Earlier research has often focused on single biomarkers or specific diseases. Most importantly, it considers advances in preclinical science, e.g., the improvements in test processes, biological characterisation, and immune microenvironment assessment. In doing so, this work provides an up-to-date overview that stresses the clinical importance of biomarkers along with their increasing role in the optimisation of clinical trials, precision medicine, and in-the-moment therapeutic decision-making. By using this approach, the study offers a forward-looking viewpoint on enhancing the therapeutic usefulness and repeatability of cancer biomarkers in addition to presenting the existing picture.</p> Summary <p>With an emphasis on their application in clinical research, therapeutic development, and patient care, the definitions of biomarkers outlined by the National Institutes of Health and the U.S. Food and Drug Administration. By identifying acceptable patients and accelerating approval procedures, biomarkers also improve clinical trials and drug development. In oncology, biomarkers are essential and required to be extensively assessed for screening, differential diagnosis, risk assessment and disease progression surveillance.</p> Graphical Abstract <p></p>